Delivery Order SPE2DB20D3111-SPE2DB25FA8PZ
- Not listed
- The Defense Logistics Agency Troop Support Medical awarded a $676 delivery order to Amerisourcebergen Drug Corp Corporate Office Division for the supply of 4,562,194,681 Febuxostat 40 mg tablets. The order is to provide 30 tablets and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania under firm fixed pricing by September 18, 2023. No additional details were provided regarding the original solicitation or whether this delivery order is associated with an existing...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the supply of 4,563,472,907 units of febuxostat 40 mg tablets, with a potential value of $1,659.19. The delivery order has a completion date of January 30, 2024. AmerisourceBergen Drug Corp, as the prime contractor, will deliver these pharmaceutical products from its Corporate Office location in Conshohocken,...
- The U.S. Department of Defense's Medical Supply Chain (VPDLATSMED-A) awarded Amerisourcebergen Drug Corp's Corporate Office Division a delivery order contract worth $3,821.00 for the supply of 4565127517 - FEBUXOSTAT 40 MG TABLET 30S. This order is part of Amerisourcebergen's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. Under this IDC, Amerisourcebergen provides a comprehensive range...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order valued at $1,972.24 for the supply of 40 mg febuxostat tablets. The contract has an ultimate completion date of November 5, 2024 and is a firm fixed price arrangement. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of 4,558,119,086 units of Febuxostat 40 mg tablets. The $2,347.52 firm fixed-price contract has an ultimate completion date of August 17, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a wide range of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4562815633 - FEBUXOSTAT 80 MG TABLET 30S, a pharmaceutical product. The contract has a ceiling value of $3,923.72 and an ultimate completion date of November 15, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The award is for the delivery of 40 milligram febuxostat tablets in 30-count packages, with a potential value of $1,423.80 and a completion date of February 2, 2024. No set-aside designation was used for this contract. Amerisourcebergen Drug Corp serves...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of the pharmaceutical product Febuxostat 40 mg tablets. The contract, valued at $2,077.84, was awarded on April 23, 2024 by the Defense Logistics Agency (DLA) Troop Support Medical, with an ultimate completion date of April 24, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025,...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide FEBUXOSTAT 80 MG TABLET 30S. The contract, valued at $1,080.77, has a completion date of March 20, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Febuxostat 80 mg tablets. The $1,100.75 firm fixed-price contract has a completion date of July 5, 2023. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a primary vehicle for providing a wide range of pharmaceutical products and medical supplies...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA8PZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Febuxostat 80 mg tablets in quantities of 30, with a ceiling value of $1,033.58. This firm fixed-price delivery order, which is set to be completed by July 23, 2025, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to fulfill federal pharmaceutical supply requirements. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs and other government healthcare systems worldwide. The company's established IDC enables flexible fulfillment of pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 7/22/25 |